Skip to main content
Calliditas Therapeutics logo

Calliditas Therapeutics — Investor Relations & Filings

Ticker · CALTX ISIN · SE0010441584 LEI · 549300PVPZO8TNT76B58 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2020-08-03 Declaration of Voting R…
Country SE Sweden
Listing ST CALTX

About Calliditas Therapeutics

https://www.calliditas.se/en/

Calliditas Therapeutics is a commercial-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for rare diseases with significant unmet medical needs. The company concentrates on orphan indications, with an initial focus on renal and hepatic diseases. Its lead product, TARPEYO® (budesonide), is approved in the U.S. for the treatment of primary immunoglobulin A nephropathy (IgAN) and is marketed as Kinpeygo® in Europe. Calliditas is advancing a pipeline of novel medications and seeks strategic partnerships to expand its development and commercialization efforts for therapies addressing conditions with few or no existing approved treatments.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document details a change in shareholding for an individual ('Bengt Julander') in Calliditas Therapeutics AB, specifically reporting the number of shares and resulting voting rights after a transaction on 31/07/2020. It explicitly mentions 'Reason for major shareholding notification' and provides percentages crossing a threshold (implied by the structure, though the threshold is 10%). This structure is characteristic of a notification regarding a significant change in ownership, which aligns with the definition of Major Shareholding Notification (MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a director's dealing report (DIRS), as it focuses on the resulting holding percentage rather than a director's personal transaction or a general earnings summary.
2020-08-03 English
Antal aktier och röster i Calliditas Therapeutics
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a short press release dated July 31, 2020, detailing an update on the total number of shares and votes following the issuance of new shares due to the over-allotment option from the IPO and the conversion of stock options. This directly relates to changes in the company's capital structure (share count). The definitions provided include 'Share Issue/Capital Change (Code: SHA)' for announcements regarding new share issues or capital changes. Since this is a direct announcement of a change in the number of shares outstanding, SHA is the most appropriate classification, rather than a general regulatory filing (RNS) or a report publication announcement (RPA), as it contains the core information itself.
2020-07-31 Swedish
Number of shares and votes in Calliditas Therapeutics
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly details changes in the number of outstanding shares due to the exercise of an over-allotment option from an IPO and the conversion of warrants. It concludes with the total number of shares and votes as of July 31, 2020. This content directly relates to changes in the company's capital structure (share count). Based on the definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate classification for announcements detailing changes in the total number of shares outstanding, whether through issuance, conversion, or repurchase.
2020-07-31 English
Calliditas omorganiserar sin ledningsgrupp
Board/Management Information Classification · 99% confidence The document is a short announcement dated July 24, 2020, titled "Calliditas omorganiserar sin ledningsgrupp" (Calliditas reorganizes its management group). It explicitly details changes in the composition of the company's senior management team, listing the new roles and members (CEO, CFO, CMO, etc.). This directly aligns with the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2020-07-24 Swedish
Calliditas reorganizes its management team
Board/Management Information Classification · 99% confidence The document explicitly announces a reorganization of the company's management team, listing the new composition of the senior team and providing quotes from the CEO regarding this change. This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management.
2020-07-24 English
Major Shareholding Notification 2020
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding for an entity named 'Gladiator' concerning 'Calliditas Therapeutics AB'. It explicitly uses the heading 'Reason for major shareholding notification' and provides 'Before the transaction' and 'After the transaction' figures, including share quantities and percentages (e.g., 4.17%). This structure is characteristic of a notification regarding a significant change in ownership that crosses a reporting threshold. Based on the provided definitions, this aligns perfectly with 'Major Shareholding Notification' (Code: MRQ). The document length (4431 chars) is substantial enough to be the notification itself, not just an announcement of one.
2020-07-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.